Collaborating to Improve Prostate Cancer Survival, Health Care Utilization

Commentary
Video

Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr, MD.

In a conversation with CancerNetwork®, Curtiland Deville Jr, MD, spoke about how collaboration across different departments at his institution helps to improve outcomes among patients who receive treatment for prostate cancer and other malignancies.

Deville, medical director of the Johns Hopkins Proton Therapy Center and clinical director of Radiation Oncology at Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, highlighted how multiple specialists communicate closely with one another to answer questions such as reducing treatment burden for patients. Additionally, he described how this kind of collaboration has demonstrated improvements in survival and health care utilization, as processes like ordering tests become more efficient with teamwork across departments.

Transcript:

At Johns Hopkins and at Sibley, I mentioned I came to Hopkins to work with world-class experts in prostate cancer management. [That means] having the reassurance that the patient is getting the best care no matter which discipline he’s seeing. In cancer management now, it is always multidisciplinary. It’s very rare that only one type of specialist is seeing a [patient with] cancer. As the specialist, we need to be working together. We need to be on the same page and in close collaboration and communication to ensure that the patient is getting the best outcome. From my perspective, how can we minimize the burden to the patient? How can we be proactive and have a very patient-centered approach in making sure they’re able to access and get the information that they need in a way they can digest and not feel like they’re being bounced around from one provider to the next [as] no one’s bringing the full picture together?

We see that outcomes are better with multidisciplinary care, whether it’s survival or even just health care utilization. Ordering tests and things become more efficient when providers communicate together [like] when we talk to the radiologists directly, when we communicate together with the medical oncologists, the radiation oncologists, and the surgical oncologists [to be] on the same page about what are the next steps for this patient’s best management. I truly believe that’s what we find here at Sibley and at Hopkins.

Recent Videos
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
Related Content